Rapamycin (Sirolimus) vs NMN/NR (Nicotinamide Mononucleotide/Riboside): Switching Between Them

Two Distinct Aging Pathways, Not Interchangeable Drugs

Rapamycin inhibits mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing kinase that regulates cellular growth, autophagy, and senescence. NMN and NR raise intracellular NAD+ levels, fueling sirtuins and mitochondrial repair enzymes. These are parallel pathways, not competing ligands at the same receptor.

The distinction matters for switching decisions. A patient who stops rapamycin does not experience NAD+ depletion, and a patient who stops NMN does not see mTOR reactivation beyond baseline. The ITP (Interventions Testing Program) at the National Institute on Aging demonstrated rapamycin extended median lifespan in mice by 9-14% depending on sex and dose initiation age 1. NAD+ precursors have shown lifespan extension in yeast and worm models but lack equivalent mammalian lifespan data from the ITP.

Dr. Matt Kaeberlein, former director of the University of Washington Healthy Aging and Longevity Research Institute, has stated: "Rapamycin remains the most reproducible pharmacological intervention for extending lifespan in laboratory mammals. NAD+ precursors address a different biology, one centered on metabolic efficiency rather than growth suppression."

Because these compounds act on separate nodes of the aging network, clinicians in the longevity space increasingly view them as complementary rather than competitive options.

Rapamycin: Clinical Evidence for Longevity Dosing

Low-dose, intermittent rapamycin has moved from transplant immunosuppression (2-5 mg daily) into off-label longevity protocols using 3-6 mg once weekly or biweekly. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024 (N=40), reported that healthy adults aged 50-85 taking 5 mg rapamycin weekly for 12 months showed improved self-reported health metrics and preserved immune function compared to placebo 2.

Rapamycin's side-effect profile at longevity doses differs from transplant doses. Common findings include mild hyperlipidemia (LDL increases of 10-20%), aphthous ulcers in approximately 15% of users, and transient glucose elevations. The Mannick et al. 2014 trial in Science Translational Medicine (N=218) demonstrated that a rapamycin analog (everolimus) at 0.5 mg daily improved influenza vaccine response in elderly adults by 20%, suggesting immune enhancement rather than suppression at low doses 3.

Monitoring requirements for rapamycin longevity protocols: fasting lipid panel at baseline, 6 weeks, and quarterly thereafter; fasting glucose or HbA1c at the same intervals; CBC with differential every 6 months.

NMN/NR: Clinical Evidence for NAD+ Repletion

NMN and NR both serve as precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme that declines 40-60% between ages 40 and 70. Yoshino et al. published in Science (2021) the first placebo-controlled trial of NMN in humans: 25 postmenopausal prediabetic women received 250 mg NMN daily for 10 weeks and showed significant improvements in skeletal muscle insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp 4.

NR (nicotinamide riboside) has a larger human trial database. The Martens et al. 2018 trial (N=24) in Nature Communications showed NR 1000 mg/day for 6 weeks raised NAD+ metabolome levels by 60% and produced a trend toward reduced aortic stiffness and systolic blood pressure in healthy middle-aged adults 5.

Side effects of NMN and NR are minimal. Mild flushing, GI discomfort, and transient headache are reported at rates below 10% in published trials. Neither compound requires routine blood monitoring, though some longevity clinicians check NAD+ metabolite levels (via whole blood or intracellular assays) to confirm bioavailability.

The primary limitation: no NMN or NR trial has demonstrated lifespan extension or hard clinical endpoints (cardiovascular events, cancer incidence, mortality) in humans. Current evidence supports biomarker improvements only.

Mechanism Comparison: mTOR Inhibition vs. NAD+ Support

Rapamycin binds FKBP12, and this complex directly inhibits mTORC1. Downstream effects include increased autophagy (cellular debris clearance), reduced senescent cell accumulation, and suppressed inflammatory cytokine output (particularly IL-6 and TNF-alpha). These effects mimic caloric restriction at the molecular level.

NMN and NR restore NAD+ pools, which activate SIRT1 through SIRT7 (the sirtuin family). Sirtuins deacetylate histones, regulate mitochondrial biogenesis via PGC-1alpha, and modulate FOXO transcription factors involved in stress resistance. NAD+ also fuels PARP enzymes involved in DNA repair.

The two pathways intersect at AMPK. Rapamycin indirectly activates AMPK by suppressing mTORC1-mediated negative feedback. NAD+/sirtuin signaling also activates AMPK through LKB1 deacetylation. This shared downstream node is why some researchers hypothesize additive benefits from combining both interventions, though controlled human data confirming this hypothesis does not yet exist 6.

One key pharmacologic difference: rapamycin has a half-life of approximately 62 hours and achieves steady-state immunologic effects over weeks. NMN has a plasma half-life of minutes (rapidly converted to NAD+), and NR has a half-life of approximately 2-3 hours. This means rapamycin's biological effects linger for 12-14 days after the last dose, while NMN/NR effects dissipate within 24-48 hours.

Switching from Rapamycin to NMN/NR

Patients switch from rapamycin to NMN/NR for several reasons: lipid elevations they find unacceptable, desire to avoid prescription monitoring, or a preference for supplements over off-label pharmaceuticals. The transition is pharmacologically uncomplicated.

Stop rapamycin. Wait 2 weeks (approximately 5 half-lives for complete clearance). Begin NMN at 250-500 mg/day or NR at 300-600 mg/day. No taper is required because rapamycin at weekly longevity doses does not produce physiologic dependence or rebound immunosuppression.

Check a lipid panel 4-6 weeks after stopping rapamycin. Hyperlipidemia typically resolves within this window. If it persists, the elevation may be unrelated to rapamycin and warrants separate workup.

The Endocrine Society does not publish guidelines on NAD+ precursor dosing because these compounds lack FDA approval for any indication. Dosing relies on published trial protocols and clinician experience 7.

Switching from NMN/NR to Rapamycin

This direction is more common. Patients often start with over-the-counter NMN or NR, find the biomarker changes modest, and seek the stronger mechanistic intervention that rapamycin represents.

Stop NMN/NR (no washout needed given rapid clearance). Obtain baseline labs: CBC, comprehensive metabolic panel, fasting lipid panel, fasting glucose, HbA1c. Begin rapamycin at 3-5 mg once weekly under physician supervision. Recheck labs at 6 weeks.

A prescribing physician should evaluate for contraindications: active infection, poorly controlled diabetes (HbA1c >8.0%), immunosuppressive therapy, or organ transplant history. Rapamycin is pregnancy category C.

The FDA approved sirolimus (Rapamune) for renal transplant rejection prophylaxis in 1999 8. All longevity use is off-label.

Can You Use Both Simultaneously?

Some longevity clinicians prescribe rapamycin (weekly) alongside daily NMN or NR. The rationale: mTOR inhibition and NAD+ repletion target non-overlapping pathways, so combined use might produce additive benefits on autophagy, mitochondrial function, and inflammation.

No randomized controlled trial has tested this combination in humans. The theoretical concern is that rapamycin-induced glucose elevation could partially offset NMN's insulin-sensitizing effect observed in the Yoshino trial. Whether this interaction is clinically meaningful at longevity doses remains unknown.

Dr. Peter Attia has discussed this combination on his podcast (The Drive), noting: "I have patients on both. The logic is sound at the pathway level. But we are operating without controlled data, and I tell every patient that explicitly."

If combining, standard practice includes the same rapamycin monitoring schedule (lipids, glucose, CBC) with attention to any new glucose dysregulation that might signal a negative interaction between mTOR inhibition and metabolic parameters.

Who Is a Better Candidate for Each Intervention

Rapamycin may be preferable for patients with: strong family history of cancer (mTOR inhibition has anti-proliferative properties), elevated inflammatory markers (hs-CRP >2.0 mg/L), or biomarker evidence of accelerated epigenetic aging (e.g., GrimAge acceleration). These patients may benefit most from autophagy upregulation and senescent cell clearance.

NMN/NR may be preferable for patients with: metabolic syndrome or insulin resistance (based on the Yoshino insulin sensitivity data), high physical activity demands (NAD+ supports mitochondrial ATP production), or reluctance to use prescription medications with monitoring requirements.

Age also influences selection. NAD+ decline accelerates after age 40, making repletion most relevant in this demographic. Rapamycin's ITP data showed lifespan benefits even when initiated at the murine equivalent of age 60, suggesting it remains effective when started later in life 9.

Safety Comparison at Standard Longevity Doses

Rapamycin (5 mg/week) carries quantifiable risks: hyperlipidemia in 30-40% of users, mouth sores in 10-20%, mild leukopenia in <5%, and theoretical (unproven at low doses) increased infection susceptibility. All effects are reversible with discontinuation.

NMN (250-1000 mg/day) and NR (300-1000 mg/day) show no serious adverse events in published trials up to 12 weeks duration. Long-term safety data beyond one year does not exist for either compound in controlled settings. A theoretical concern raised by some oncologists: sustained NAD+ elevation might fuel cancer cell metabolism in patients with occult malignancies, though no human data supports this risk 10.

The safety asymmetry is clear. Rapamycin is a prescription drug with real (if manageable) side effects and monitoring requirements. NMN/NR behaves like a well-tolerated supplement with minimal acute risk but unknown long-term consequences.

Cost and Access Considerations

Rapamycin requires a physician prescription and off-label justification. Generic sirolimus costs $40-120/month for weekly longevity dosing through compounding pharmacies. Insurance does not cover off-label longevity use.

NMN costs $30-100/month depending on brand, dose, and purity verification (third-party testing for actual NMN content is recommended, as supplement quality varies). NR (marketed as Niagen by ChromaDex/Tru Niagen) costs $40-60/month at 300 mg/day. Both are available without prescription.

The FDA issued a statement in November 2022 excluding NMN from the dietary supplement definition because it was being investigated as a new drug. This regulatory decision has created market uncertainty, though NMN remains widely sold online 11.

Monitoring Protocols After Switching

After switching to rapamycin from NMN/NR, implement this monitoring schedule: baseline labs before first dose, repeat at 6 weeks, then quarterly for the first year, then biannually if stable. Key values to track: total cholesterol, LDL, triglycerides, fasting glucose, HbA1c, WBC count, and platelet count.

After switching to NMN/NR from rapamycin, confirm lipid normalization at 4-6 weeks post-discontinuation. Optional NAD+ metabolite testing (available through specialty labs) at baseline and 8 weeks can confirm absorption and cellular uptake. No routine blood monitoring is otherwise required by clinical evidence.

Patients on either intervention should maintain annual comprehensive metabolic panels, cancer screening per USPSTF guidelines 12, and periodic assessment of functional aging biomarkers if available through their clinician.